REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE)

Clinical trials for REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) trials appear

Sign up with your email to follow new studies for REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

Old drug, new hope for rare skin cancer?

Disease control Completed

This study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, rep…

Matched conditions: REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE)

Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control

Last updated Jun 24, 2026 02:17 UTC

REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE)

Get alerted when new REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) trials appear

Old drug, new hope for rare skin cancer?